August 21, 2018
…. Although the gothic novella is far less fun when markets act like it’s their blueprint. Sector stocks have lately been alternating between the dreaded and the benign!
Out and about: Organogenesis, (potential symbol: ORGO) a wound care and skin graft biotech is going public again is merging with a special vehicle created by Avista Capital which will invest 92M. Organogenesis had gone private (2002) amid financial difficulties
Spare the SELL call, ruin the portfolio – SUBSCRIBE!
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through!
Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates;
.... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 20, 2018
I answer one question, in which company should investors put, keep and commit their money!
Re-framing the main takeaway … pricing, volume and volatility as “our” universe suffers from “tourist” investing.
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 16, 2018
Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric. I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds! Now I’m asking you to commit: http://www.regmedinvestors.com/create-account
August 15, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies Thirty-five (35) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies; The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
